Psoriasis: key endpoint results by drug

The key endpoints of Psoriasis trials, with each approved or late-stage drug's result from its own trial: the lead dose against placebo (or the trial's active comparator), the week, and the arm size. These are the same rows as the drug comparison, for every drug at once. To set chosen drugs side by side, with every shared endpoint, use the comparison. The drug list and pipeline are on the Psoriasis page.

PASI 75 (induction)

PASI 75 in Psoriasis: 28 drugs, each from its own trial
DrugResultControlDifferenceDose · week · nTrial
adalimumab77.8%11.5%+66.3Eow · wk 12 · n 338NCT01646073 Phase 3, primary
apremilast33.1%5.3%+27.8wk 16 · n 562NCT01194219 Phase 3, primary
baricitinib54.1%16.7%+37.410 mg · wk 12 · n 61NCT01490632 Phase 2, primary
bimekizumab76.9%2.4%+74.5320 mg Q4W · wk 4 · n 321NCT03370133 Phase 3, secondary
brepocitinib60%13%+4760 mg Once Daily (QD) Followed by 30 mg QD · wk 12 · n 25NCT02969018 Phase 2, secondary
Calcipotriene/Betamethasone Dipropionate Foam50%14.3%+35.7wk 16 · n 14NCT03441789 Phase 4, primary
certolizumab pegol66.7%5%+61.7400 mg Q2W · wk 12 · n 167NCT02346240 Phase 3, primary
deucravacitinib53%9.4%+43.6wk 16 · n 511NCT03611751 Phase 3, primary
Envudeucitinib56.4%0%+56.440mg QD · wk 12 · n 39NCT05600036 Phase 2, primary
etanercept57%11%+46wk 12 · n 106NCT00078819 Phase 3, primary
Girocitinib35.5%21.4%+14.1wk 12 · n 31NCT05772520 Phase 2, primary
guselkumab84.1%6.3%+77.8100 mg · wk 16 · n 63NCT02325219 Phase 3, secondary
icotrokinra65.1%9.3%+55.8100 mg QD · wk 16 · n 43NCT05223868 Phase 2, primary
infliximab81%2.2%+78.8wk 10 · n 84NCT01177800 Phase 3, primary
ixekizumab84.2%7.3%+76.980 mg every 4 weeks · wk 12 · n 386NCT01646177 Phase 3, primary
mirikizumab82.5%9.3%+73.2250 mg Q4W · wk 16 · n 423NCT03482011 Phase 3, secondary
netakimab77.6%0%+77.6Q2W · wk 12 · n 85NCT03390101 Phase 3, primary
Piclidenoson8.5%6.9%+1.62 mg · wk 12 · n 141NCT01265667 Phase 2/3, primary
risankizumab85.2%85.7% (Ustekinumab)—wk 16 · n 54NCT04435600 Phase 3, primary
Roflumilast (Zoryve)41.6%7.6%+340.3% cream · wk 8 · n 255NCT04211363 Phase 3, secondary
secukinumab77.1%4.9%+72.2300mg · wk 12 · n 323NCT01358578 Phase 3, primary
sonelokimab84.9%90.6% (Secukinumab)—120 mg · wk 12 · n 53NCT03384745 Phase 2, secondary
Tapinarof36.1%10.2%+25.9wk 12 · n 340NCT03956355 Phase 3, secondary
tildrakizumab66.3%4.4%+61.9100 mg · wk 16 · n 89NCT01225731 Phase 2, primary
tofacitinib63.6%5.6%+5810 mg BID · wk 12 · n 330NCT01241591 Phase 3, primary
ustekinumab75.7%3.7%+7290 mg · wk 12 · n 411NCT00307437 Phase 3, primary
Voclosporin13.3%3.5%+9.80.2 · wk 12 · n 105NCT00244842 Phase 3, primary
zasocitinib67.3%5.8%+61.530 mg · wk 12 · n 52NCT04999839 Phase 2, primary

Drugs checked with no result here: 19 not posted, 36 not reported, 14 trial running.

PASI 90 (induction)

PASI 90 in Psoriasis: 21 drugs, each from its own trial
DrugResultControlDifferenceDose · week · nTrial
adalimumab61.8%54.2% (EU RPP)—wk 16 · n 267NCT02581345 Phase 3, secondary
apremilast55.9%5.1% (APR)—wk 16 · n 118NCT04908475 Phase 4, primary
bimekizumab85%4.8%+80.2320 mg Q4W · wk 16 · n 321NCT03370133 Phase 3, primary
brepocitinib20%4.3%+15.760 mg Once Daily (QD) Followed by 30 mg QD · wk 16 · n 25NCT02969018 Phase 2, secondary
certolizumab pegol55.4%4.5%+50.9400 mg Q2W · wk 16 · n 87NCT02326272 Phase 3, secondary
deucravacitinib27%2.7%+24.3wk 16 · n 511NCT03611751 Phase 3, secondary
etanercept27%7%+20wk 12 · n 106NCT00078819 Phase 3, secondary
guselkumab70%2.4%+67.6100 mg · wk 16 · n 496NCT02207244 Phase 3, primary
icotrokinra46.5%2.3%+44.2100 mg QD · wk 16 · n 43NCT05223868 Phase 2, secondary
ixekizumab72.8%42.2% (Ustekinumab)—wk 12 · n 136NCT02561806 Phase 3, primary
mirikizumab64.3%6.5%+57.8250 mg Q4W · wk 16 · n 423NCT03482011 Phase 3, primary
picankibart80.3%a2%+78.3wk 16NCT05645627 Phase 3, primary
risankizumab75.3%4.9%+70.4wk 16 · n 304NCT02684370 Phase 3, primary
Roflumilast (Zoryve)22.4%2.3%+20.10.3% cream · wk 8 · n 255NCT04211363 Phase 3, secondary
secukinumab79%57.3% (Ustekinumab)—300 mg · wk 16 · n 334NCT02074982 Phase 3, primary
sonelokimab69.8%64.2% (Secukinumab)—120 mg · wk 12 · n 53NCT03384745 Phase 2, secondary
Tapinarof18.8%1.6%+17.2wk 12 · n 340NCT03956355 Phase 3, secondary
tildrakizumab38.6%2.4%+36.2100 mg · wk 16 · n 88NCT01225731 Phase 2, secondary
tofacitinib39.4%0.6%+38.910 mg · wk 16 · n 360NCT01276639 Phase 3, secondary
ustekinumab54.1%5.4%+48.7Half-Standard Dosage · wk 12 · n 37NCT01090427 Phase 3, secondary
zasocitinib46.2%0%+46.230 mg · wk 12 · n 52NCT04999839 Phase 2, secondary

Drugs checked with no result here: 24 not posted, 38 not reported, 14 trial running.

PASI 100 (induction)

PASI 100 in Psoriasis: 13 drugs, each from its own trial
DrugResultControlDifferenceDose · week · nTrial
adalimumab18.4%2.7% (Methotrexate)—0.8 mg/kg · wk 16 · n 38NCT01251614 Phase 3, secondary
bimekizumab61.7%48.9% (Secukinumab)—320 mg Q4W · wk 16 · n 373NCT03536884 Phase 3, primary
deucravacitinib10.2%1.2%+9wk 16 · n 511NCT03611751 Phase 3, secondary
guselkumab50%0%+50wk 16 · n 62NCT02905331 Phase 3, secondary
icotrokinra23.3%0%+23.3100 mg QD · wk 16 · n 43NCT05223868 Phase 2, secondary
ixekizumab35%0%+3580 mg every 4 weeks · wk 12 · n 386NCT01646177 Phase 3, secondary
mirikizumab32.4%0.9%+31.5250 mg Q4W · wk 16 · n 423NCT03482011 Phase 3, secondary
risankizumab35.9%0%+35.9wk 16 · n 304NCT02684370 Phase 3, secondary
secukinumab23.5%0%+23.5wk 12 · n 51NCT02267135 Phase 3, secondary
sonelokimab37.7%28.3% (Secukinumab)—120 mg · wk 12 · n 53NCT03384745 Phase 2, secondary
tildrakizumab14.8%0%+14.8100 mg · wk 16 · n 88NCT01225731 Phase 2, secondary
ustekinumab29.9%26.2% (Ustekinumab)—wk 16 · n 281NCT04607980 Phase 3, secondary
zasocitinib32.7%0%+32.730 mg · wk 12 · n 52NCT04999839 Phase 2, secondary

Drugs checked with no result here: 30 not posted, 40 not reported, 14 trial running.

sPGA 0/1 (induction)

sPGA 0/1 in Psoriasis: 25 drugs, each from its own trial
DrugResultControlDifferenceDose · week · nTrial
adalimumab60.5%40.5% (Methotrexate)—0.8 mg/kg · wk 16 · n 38NCT01251614 Phase 3, primary
apremilast21.6%4.1%+17.530 mg · wk 16 · n 297NCT03721172 Phase 3, primary
baricitinib34.8%14.7%+20.110 mg · wk 12 · n 69NCT01490632 Phase 2, secondary
bimekizumab84.1%4.8%+79.3320 mg Q4W · wk 16 · n 321NCT03370133 Phase 3, primary
brepocitinib10.3%14.7%−4.40.1% QD · wk 12 · n 29NCT03850483 Phase 2, secondary
certolizumab pegol57.9%4.2%+53.7400 mg Q2W · wk 16 · n 88NCT02326298 Phase 3, primary
desoximetasone38.7%34.1%+4.6wk 4 · n 106NCT02932462 Phase 3, primary
deucravacitinib49.5%8.6%+40.9wk 16 · n 511NCT03611751 Phase 3, primary
Envudeucitinib53.8%7.9%+45.940mg QD · wk 12 · n 39NCT05600036 Phase 2, secondary
etanercept28.9%3.6%+25.350 mg SC QW · wk 16 · n 83NCT01690299 Phase 3, secondary
guselkumab85.7%7.1%+78.6100 mg · wk 16 · n 42NCT01483599 Phase 2, primary
Halobetasol Propionate Lotion36.5%8.1%+28.4wk 8 · n 143NCT02514577 Phase 3, primary
halobetasol propionate/tazarotene35.8%7.0%+28.8wk 8 · n 135NCT02462070 Phase 3, primary
infliximab88.1%6.7%+81.4wk 10 · n 84NCT01177800 Phase 3, secondary
ixekizumab75.4%6.7%+68.780 mg every 4 weeks · wk 12 · n 386NCT01646177 Phase 3, primary
mirikizumab69.3%6.5%+62.8250 mg Q4W · wk 16 · n 423NCT03482011 Phase 3, primary
Piclidenoson6.4%3.5%+2.92 mg · wk 16 · n 141NCT01265667 Phase 2/3, secondary
risankizumab87.8%7.8%+80wk 16 · n 304NCT02684370 Phase 3, primary
secukinumab62.5%2.8%+59.7300mg · wk 12 · n 323NCT01358578 Phase 3, primary
Tapinarof35.4%6%+29.4wk 12 · n 340NCT03956355 Phase 3, primary
tildrakizumab61.8%2.2%+59.6100 mg · wk 16 · n 89NCT01225731 Phase 2, secondary
tofacitinib68.2%14.9%+53.210 mg BID · wk 12 · n 330NCT01241591 Phase 3, primary
ustekinumab67.6%5.4%+62.2Half-Standard Dosage · wk 12 · n 37NCT01090427 Phase 3, primary
Voclosporin35%a6%+29wk 12NCT00408187 Phase 3, primary
zasocitinib51.9%3.8%+48.130 mg · wk 12 · n 52NCT04999839 Phase 2, secondary

Drugs checked with no result here: 15 trial running, 22 not posted, 35 not reported.

DLQI, change (induction)

DLQI, change in Psoriasis: 18 drugs, each from its own trial
DrugResultControlDifferenceDose · week · nTrial
adalimumab-4.8-4.2−0.6wk 16 · n 49NCT00735787 Phase 4, secondary
apremilast-6.6-2.1−4.530 mg BID · wk 16 · n 556NCT01194219 Phase 3, secondary
baricitinib-5.1-1.7−3.410 mg · wk 12 · n 68NCT01490632 Phase 2, secondary
Calcipotriene/Betamethasone Dipropionate Foam36−3wk 16 · n 14NCT03441789 Phase 4, secondary
certolizumab pegol-10-3.8−6.2400 mg Q2W · wk 16 · n 87NCT02326272 Phase 3, secondary
deucravacitinib-10.2-2.9−7.312 mg QD · wk 12 · n 44NCT02931838 Phase 2, secondary
etanercept-7.8-3.9−3.950 mg SC QW · wk 16 · n 80NCT01690299 Phase 3, secondary
guselkumab-11.2-2.6−8.6100 mg · wk 16 · n 495NCT02207244 Phase 3, secondary
infliximab-8-1.5−6.5wk 10 · n 84NCT01177800 Phase 3, secondary
ixekizumab-9.6-1.7−7.980 mg every 4 weeks · wk 12 · n 375NCT01646177 Phase 3, secondary
mirikizumab-9.6-1.1−8.6300 mg · wk 16 · n 49NCT02899988 Phase 2, secondary
risankizumab-17-9.7 (Fumaderm)—wk 16 · n 59NCT03255382 Phase 3, secondary
Roflumilast (Zoryve)-2.6-1.4−1.20.3% · wk 12 · n 58NCT03638258 Phase 2, secondary
secukinumab-13.2-2.0−11.2300 mg · wk 12 · n 41NCT03589885 Phase 3, secondary
tildrakizumab-8.51−9.5100 mg · wk 16 · n 88NCT01225731 Phase 2, secondary
tofacitinib-8.9-1.9−710 mg · wk 16 · n 357NCT01276639 Phase 3, secondary
ustekinumab-9-0.5−8.590 mg · wk 12 · n 402NCT00307437 Phase 3, secondary
zasocitinib-8.9-4.9−430 mg · wk 12 · n 47NCT04999839 Phase 2, secondary

Drugs checked with no result here: 16 trial running, 24 not posted, 39 not reported.

  1. a From a reviewed publication or company release; CT.gov has no posted result for this endpoint.
  2. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  3. Rows are in drug-name order, not ranked. Difference is the lead arm minus placebo, in the endpoint's unit. 97 approved or late-stage drugs with a featured trial in Psoriasis were checked; results come from ClinicalTrials.gov posted results unless marked. Updated 2026-11-20. How results are chosen: methodology.